Merrill rates Angiotech at buy

Merrill Lynch analyst Hari Sambasivam rated Angiotech Pharmaceuticals Inc. at a buy. Boston Scientific reported fourth-quarter 2005 Taxus sales of $606 million, broadly in line with Merrill's estimates of $601 million. Boston does not anticipate delay of the approval of the Taxus Liberté stent, estimated for October 2006. Shares of the Vancouver, B.C., pharmaceutical company were down 18 cents, or 1.15%, at $15.50 on volume of 787,237 shares versus the three-month running average of 592,510 shares. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.